Posted by Michael Wonder on 09 Feb 2016
US FDA accepts for review Otsuka and Lundbeck's sNDA filing for labeling update of Rexulti (brexpiprazole) for maintenance treatment of schizophrenia
8 February 2016 - Under the Prescription Drug User Fee Act (PDUFA), the PDUFA date is 23 September 2016.
For more details, go to: https://www.lundbeck.com/global
